The National Blood Authority (NBA) has agreed arrangements with Grifols Australia Pty Ltd for the introduction of their Subcutaneous Immunoglobulin (SCIg) product, Xembify 20%, under the national blood arrangements. Supply to the Australian market is anticipated to commence in January 2024. This additional product will strengthen and diversify the supply of SCIg in Australia to ensure eligible patients continue to have access to Ig treatment.

Xembify 20% (Grifols) is approved by the Therapeutics Goods Administration (TGA) in line with the usual high standards of safety and quality. The introduction of Xembify will be in addition to the currently available suite of imported SCIg products, namely Hizentra 20% (CSL Behring), Cuvitru 20% (Takeda) and the new domestic SCIg product Hizentra AU (CSL Behring).

For information about the transition from Evogam to Hizentra AU go to https://www.allergy.org.au/about-ascia/info-updates/transition-from-evogam-to-hizentra-au-scig-products

Please see the NBA website for further information about the introduction of Xembify. Announcements on BloodSTAR and BloodNet, as well as relevant advice to stakeholder groups will occur over the coming months in preparation for the introduction of Xembify 20%. Communications will also be sent to Approved Health Providers and Red Cross Lifeblood to prepare their systems for this change, as further details are available.

This news item was issued on 22 August 2023 by Jill Smith, CEO of ASCIA, the peak professional body for clinical immunology and allergy in Australia and New Zealand.